484 Preliminary efficacy of the IL-15 superagonist SO-C101 in combination with pembrolizumab in patients with advanced/metastatic solid tumors

• Stephane Champiat,
• Aurélien Marabelle,
• Aung Naing,
• Filip Janku,
• Patricia LoRusso,
• David Béchard,
• Elena Garralda,
• Vladimir Galvao,
• Peter Grell,
• Richard Sachse,
• Joachim Kiemle-Kallee

Affiliations

Stephane Champiat

1 Medical Oncology and Drug Development Department, Institut Gustave Roussy, Villejuif, France

Aurélien Marabelle

17 Drug Development, Gustave Roussy Cancer Center, Villejuif, France

Aung Naing

Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA

Filip Janku

Department of Investigational Cancer Therapeutics, University of Texas at MD Anderson Cancer Center, Houston, Texas, USA

Patricia LoRusso

Department of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USA

David Béchard

2Cytune Pharma, Nantes, France

Elena Garralda

6Vall d’Hebron Institute of Oncology, Barcelona, Spain

Vladimir Galvao

1Hospital Universitari Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Barcelona, Spain

Peter Grell

4Masaryk Memorial Cancer Institute (MMCI), Brno, CZE, Brno, Czech Republic

Richard Sachse

6SOTIO Biotech AG, Basel, Switzerland, Basel, Switzerland

Joachim Kiemle-Kallee

6SOTIO Biotech AG, Basel, Switzerland, Basel, Switzerland